Overview A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma Status: Completed Trial end date: 2018-06-26 Target enrollment: Participant gender: Summary To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma. Phase: Phase 2 Details Lead Sponsor: CelgeneCelgene CorporationTreatments: BB 1101DexamethasoneDexamethasone 21-phosphateDexamethasone acetateLenalidomideThalidomide